Clinical Trial Patient Screening via Genome Analysis
QIAGEN performs genome sequencing and analyzes the sequenced DNA to help identify patients who have variants of interest compared to a reference genome, and thus could have the protein that the cryo-EM and LAMMPS output have identified as being of interest. By speeding the identification of patients who have the right protein and thus meet the criteria for a clinical trial, this analysis can speed an important aspect of clinical trials, reduce trial costs, and lead to more effective targeted treatments with fewer undesirable side effects.
Product and Performance Information
Performance varies by use, configuration and other factors. Learn more at www.Intel.com/PerformanceIndex.